Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type 2 diabetes.
Related Posts
Block shares soar 10% on entry into S&P 500
Block is joining the S&P 500, replacing Hess as of July 23.
Trump threatens Russia with sanctions, tariffs if Putin doesn’t end Ukraine war
The war in Ukraine began with an invasion by Russia in February 2022. More than 240,000 soldiers have been killed on both sides, according to […]
Buy this chipmaker as demand for autos chips picks up, Loop Capital says
NXP Semiconductors “should grow slightly faster” than the overall automotive semiconductor market in the long run, analyst Gary Mobley said.